DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Thursday morning. The firm issued a hold rating on the stock.

Several other brokerages have also weighed in on DBVT. JMP Securities restated a “market outperform” rating and issued a $10.00 price target on shares of DBV Technologies in a research note on Tuesday, December 10th. HC Wainwright raised their price objective on DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, October 24th.

DBV Technologies Stock Up 29.8 %

Shares of DBVT stock opened at $4.97 on Thursday. The stock has a fifty day moving average of $3.32 and a 200 day moving average of $3.82. The firm has a market capitalization of $102.23 million, a price-to-earnings ratio of -1.10 and a beta of 0.64. DBV Technologies has a 52 week low of $2.20 and a 52 week high of $9.49.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.